306 related articles for article (PubMed ID: 11131752)
1. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
Wang RF; Serle JB; Gagliuso DJ; Podos SM
J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
[TBL] [Abstract][Full Text] [Related]
2. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
3. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
[TBL] [Abstract][Full Text] [Related]
4. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials.
Zabriskie N; Netland PA;
Adv Ther; 2003; 20(2):92-100. PubMed ID: 12836809
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
Cheng JW; Li Y; Wei RL
Ophthalmic Res; 2009; 42(2):99-105. PubMed ID: 19546601
[TBL] [Abstract][Full Text] [Related]
6. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
7. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Susanna R; Sheu WP;
Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
[TBL] [Abstract][Full Text] [Related]
8. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
Shin DH; Feldman RM; Sheu WP;
Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
[TBL] [Abstract][Full Text] [Related]
10. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
11. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
14. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
15. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.
Petounis A; Mylopoulos N; Kandarakis A; Andreanos D; Dimitrakoulias N
J Glaucoma; 2001 Aug; 10(4):316-24. PubMed ID: 11558817
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual comparison of the effects of a fixed dorzolamide-timolol combination and latanoprost on intraocular pressure after small incision cataract surgery.
Rainer G; Menapace R; Findl O; Petternel V; Kiss B; Georgopoulos M
J Cataract Refract Surg; 2001 May; 27(5):706-10. PubMed ID: 11377900
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Maus TL; Nau C; Brubaker RF
Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
